ASBP — Aspire Biopharma Holdings Cashflow Statement
0.000.00%
- $16.86m
- $25.13m
Annual cashflow statement for Aspire Biopharma Holdings, fiscal year end - December 31st, millions except per share.
2020 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | |
| Standards: | — | USG | USG | USG |
| Status: | fx Preliminary | Final | Final | Final |
| Net Income/Starting Line | — | 3.34 | 4.46 | -12.5 |
| Non-Cash Items | — | -4.32 | -5.8 | 9.45 |
| Unusual Items | ||||
| Equity in Net Earnings/Losses | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | — | -0.432 | 0.687 | 1.03 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | — | -1.41 | -0.653 | -2.05 |
| Other Investing Cash Flow Items | — | -295 | 285 | 13.8 |
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | — | -295 | 285 | 13.8 |
| Financing Cash Flow Items | — | 297 | 0 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | — | 297 | -285 | -11.7 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | — | 0.497 | -0.497 | 0 |